Formosa Pharmaceuticals Investors
Financials
Consolidated Financial Statements
- 2026 Q1 Consolidated Financial Statements
- 2025 Q4 Consolidated Financial Statements
- 2025 Q3 Consolidated Financial Statements
- 2025 Q2 Consolidated Financial Statements
- 2025 Q1 Consolidated Financial Statements
- 2024 Q4 Consolidated Financial Statements
- 2024 Q3 Consolidated Financial Statements
- 2024 Q2 Consolidated Financial Statements
- 2024 Q1 Consolidated Financial Statements
- 2023 Q4 Consolidated Financial Statements
- 2023 Q3 Consolidated Financial Statements
- 2023 Q2 Consolidated Financial Statements
- 2022 Q4 Consolidated Financial Statements
- 2022 Q2 Consolidated Financial Statements
- 2021 Q4 Consolidated Financial Statements
- 2021Q2 Consolidated Financial Statements
- 2020 Consolidated Financial Statements
- 2019 Consolidated Financial Statements
Parent Company Only Financial Statements
News Highlight
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
2026-08-28
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers TSY-110 is positioned to become the first biosimilar alternative to Roche’s Kadcyla® (ado-trastuzumab emtansine)
